Advertisement

Retinoid-Mediated Signaling and CD38 Expression

  • Kapil Mehta
Chapter

Abstract

CD38 was initially identified more than two decades back when murine monoclonal antibodies (mAbs) were being employed to define newer surface molecules expressed by the lymphocytes during various developmental stages. One such mAb (T10) was successfully employed in the analysis of distribution [1] and biochemical characterization of CD38 antigen [2]. The conclusions derived from the biochemical analysis of the molecule were independently confirmed by cloning of a cDNA for human CD38 in 1990 [3]. On the basis of its expression and allocation among immune cells, CD38 was referred to as an “activation marker” and till recently was used for phenotyping the differentiation state of lymphocytes and classifying leukemias.

Keywords

Retinoic Acid CD38 Expression Acute Promyelocytic Leukemia CD38 Antigen CD38 Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Refrences

  1. 1.
    Reinherz EL, Kung PC, Goldstein G, Levey RH and Schlossman SF. 1980. Discrete stages of intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T lineage. Proc. Natl. Acad. Sci. USA 11: 1588–1592.CrossRefGoogle Scholar
  2. 2.
    Terhorst C, van Agthoven A, Le Clair K, Snow P, Reinherz EL and Schlossman SF. 1981. Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell 23:771–778.PubMedCrossRefGoogle Scholar
  3. 3.
    Jackson D and Bell JI. 1990. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with unusual discontinuous pattern of expression during lymphocyte differentiation. J. Immunol. 144: 2811–2817.PubMedGoogle Scholar
  4. 4.
    States DJ, Walseth TF and Lee HC. 1992. Similarities in amino acid sequences of Aplysia ADP ribosyl cyclase and human lymphocyte antigen CD38. Trends Biochem. Sci. 17: 495.PubMedCrossRefGoogle Scholar
  5. 5.
    Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walseth TF and Lee HC. 1993. Formation and hydrolysis of cyclic ADP ribose by lymphocyte antigen CD38. Science 262: 1056–1059.PubMedCrossRefGoogle Scholar
  6. 6.
    Zocchi E, Franco L, Guida L, Benatti U, Bargellesi A, Malavasi F, Lee HC and De Flora F. A single protein immunologically identified as CD38 displays NAD+-glycohydrolase, ADP ribosyl cyclase and cyclic ADP-ribose hydrolase activities in the auter surface of human erythrocytes. Biochem. Biophys. Res. Commun. 196: 1459–1465.Google Scholar
  7. 7.
    Ramaschi G, Torti M, Tolnai Festetics E, Sinigaglia F, Malavasi F and Balduini C. 1996. Expression of cyclic ADP-ribose-synthetizing CD38 molecule of human platelet membrane. Blood 87: 2308–2313.PubMedGoogle Scholar
  8. 8.
    Dianzani U, Funaro A, DiFranco D, Garbarino G, Bragardo M, Redoglia V, Buonfiglio D, DeMonte LB, Piled A and Malavasi F. 1994. Interaction between endothelium and CD4+TD45RA+ lymphocytes. J. Immunol. 22: 952–959.Google Scholar
  9. 9.
    Ausiello CM, Urbani F, LaSala A, Funaro A and Malavasi F. 1995. CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes. Eur. J. Immunol. 25: 1477–1480.PubMedCrossRefGoogle Scholar
  10. 10.
    Konopleva M, Estrov Z, Zhao S, Andreeff M and Mehta K. 1998. Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J. Immunol. 161:4702–4708.PubMedGoogle Scholar
  11. 11.
    Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, Dianzani U, Stockinger H and Malavasi F. 1998. Human CD38 (ADP ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J. Immunol. 160: 395–402.PubMedGoogle Scholar
  12. 12.
    Deaglio S, Mehta K and Malavasi F. 2001. Human CD38: a (r)evolutionary story of enzyme and receptor. Leuk. Res. 25: 1–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Funaro A, Ferrero E, Mehta K and Malavasi F. 2000. Schematic portrait of CD38 and related molecules. Chem. Immunol. 75: 256–273.PubMedCrossRefGoogle Scholar
  14. 14.
    Podesta M, Zocchi E, Pitto A, Usai C, Franco L, Bruzzone S, Guida L, Bacigalupo A, Scadden DT, Walseth TF and De Flora A, Daga A. 2000. Extracellular cyclic ADP-ribose increases intracellular free calcium and stimulates proliferation of human hematopoietic progenitors. FASEB Lett. 14: 680–690.Google Scholar
  15. 15.
    Okamoto H, Takasawa S, Nata K, Tohgo A and Noguchi N. 2000. Physiological and pathological significance of the CD38-cyclic ADP-ribose signaling system. Chem. Immunol. 75: 122–145.Google Scholar
  16. 16.
    Antonelli A, Baj G, Marchetti P, Fallahi P, Surico N, Pupilli C, Malavasi F and Ferrannini E. 2001. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 50: 985–995.PubMedCrossRefGoogle Scholar
  17. 17.
    An NH, Han MK, Urn C, Park BH, Park BJ, Kim HK and Kim UH. 2001. Significance of ecto-cyclase activity of CD38 in insulin secretion of mouse pancreatic islet cells. Biochem. Biophys. Res. Commun. 282: 781–786.PubMedCrossRefGoogle Scholar
  18. 18.
    Ibrahim S, Keating M, Do KA, O’Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM and Albitar M. 2001. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98: 181–186.PubMedCrossRefGoogle Scholar
  19. 19.
    Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Litchman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini, M and Chiorazzi N. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 91: 1840–1847.Google Scholar
  20. 20.
    Kramer G, Steiner G, Fodinger D, Fiebiger E, Rappersberger C, Binder S, Hofbauer J and Marberger M. 1995. High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J. Urol. 154: 1636–1641.PubMedCrossRefGoogle Scholar
  21. 21.
    Bofill M and Borthwick NJ. 2000. CD38 in health and disease. Chem. Immunol. 75: 218–234.PubMedCrossRefGoogle Scholar
  22. 22.
    Altucci L and Gronemeyer H. 2001. The promise of retinoids to fight against cancer. Nature Rev. 1: 181–193.CrossRefGoogle Scholar
  23. 23.
    Collinwood TN, Urnov FD and Wolffe AP. 1999. Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J. Mol. Edocrinol. 23:255–275.CrossRefGoogle Scholar
  24. 24.
    Chambon P. 1996. A decade of molecular biology of retinoic acid receptors. FASEB J. 10: 940–954.PubMedGoogle Scholar
  25. 25.
    Melnick A and Licht JD. 1999. Deconstructing a disease. RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167–3215.PubMedGoogle Scholar
  26. 26.
    Boylan JF and Gudas LJ. 1991. Overexpression of the CRABP-1 results in a reduction in differentiation specific gene expression in F9 teratocarcinoma cells. J. Cell Biol. 112:965–979.PubMedCrossRefGoogle Scholar
  27. 27.
    Ozpolat B, Lopez-Berestein G and Mehta K. 2001. ATRA(ouble) in the treatment of acute promyelocytic leukemia cells. J. Biol. Regul. Homeost. Agents 15: 107–122.PubMedGoogle Scholar
  28. 28.
    Glass CK, Rose DW and Rosenfeld MG. 1997. Nucelar receptors coactivators. Curr. Opin. Cell Biol. 9: 222–232.PubMedCrossRefGoogle Scholar
  29. 29.
    Collingwood TN, Urnov FD and Wolffe AP. 1999. Nucelar receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J. Mol. Endorinol. 23:255–275.CrossRefGoogle Scholar
  30. 30.
    Malavasi F, Funaro A, Rogerro S, Horenstein A, Calosso L and Mehta K. 1994. CD38: A glycoprotein in search of a function. Immunol. Today 15: 95–97.PubMedCrossRefGoogle Scholar
  31. 31.
    Mehta K, McQueen T, Neamati N, Collins S and Andreeff M. 1996. Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Diffren. 7: 179–186.Google Scholar
  32. 32.
    Drach J, Zhao S, Malavasi F and Mehta K. 1993. Rapid induction of CD38 antigen on myeloid leukemia cells by all trans-retinoic acid. Biochem. Biophys. Res. Commun. 195: 545–550.PubMedCrossRefGoogle Scholar
  33. 33.
    Hemmi H and Brietman TR. 1982. Induction by retinoic acid of NAD-glycohydrolase activity of myelomonocytic cell lines HL-60, THP-1 and U937, and fresh human acute promyelocytic leukemia cells in primary culture. Biochem. Biophys. Res. Commun. 109: 669–674.PubMedCrossRefGoogle Scholar
  34. 34.
    Kontani K, Nishina H, Ohoka Y, Takahashi K and Katada T. 1993. NAD-glycohydrolase specifically induced by retinoic acid in human leukemic HL-60 cells. Identification of the NAD-glycohydrolase as leukocyte cell surface antigen CD38. J. Biol. Chem. 268: 16895–16898.PubMedGoogle Scholar
  35. 35.
    Drach J, McQueen T, Engel H, Andreeff M, Robertson K, Collins SJ, Malavasi F and Mehta K. 1994. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. Cancer Res. 54: 1746–1752.PubMedGoogle Scholar
  36. 36.
    Umar S, Malavasi F and Mehta K. 1996. Post-translational modification of CD38 protein into a high molecular weight form alters its catalytic properties. J. Biol. Chem. 271: 15922–15927.PubMedCrossRefGoogle Scholar
  37. 37.
    Mehta K, McQueen T, Manshouri T, Andreeff M, Collins S and Albitar M. 1997. Involvement of retinoic acid receptor-alpha-mediated signaling pathway in induction of CD38 cell-surface antigen. Blood 89: 3607–3614.PubMedGoogle Scholar
  38. 38.
    Mehta K and Berestein GL. 1986. Expression of tissue transglutaminase in cultured monocytic leukemia (THP-1) cells during differentiation. Cancer Res. 46:1388–1394.PubMedGoogle Scholar
  39. 39.
    Davies PJA, Murtaugh MP, Moore WT, Johnson GS and Lucas D. 1985. Retinoic acid-induced expression of tissue transglutaminase in human promyelocytic leukemia (HL-60) cells. J. Biol. Chem. 260: 5166–5174.PubMedGoogle Scholar
  40. 40.
    Mehta K. 2000. Retinoid-mediated signaling in CD38 antigen expression. Chem. Immunol. 75:20–38.PubMedCrossRefGoogle Scholar
  41. 41.
    Kishimoto H, Hoshino S, Ohori M, Kontani K, Nishina H, Suzawa M, Kato S and Katada T. 1997. Molecular mechanism of human CD38 gene expression by retinoic acid. J. Biol. Chem. 273:15429–14434.CrossRefGoogle Scholar
  42. 42.
    Ferrero E, Sccucci F and Malavasi F. 2000. The making of leukocyte receptor: origin, genes and regulation of human CD38 and related molecules. Chem. Immunol. 75:1–19.PubMedCrossRefGoogle Scholar
  43. 43.
    Ernst P and Smale ST. 1995. Combinatorila regulation of transcription: general aspects of transcriptional control. Immunity 2: 311–319.PubMedCrossRefGoogle Scholar
  44. 44.
    Stoeckler JD, Stoeckler HA, Kouttab N and Maizel AL. 1996. Dihydroxyvitamin D3 modulates CD38 expression on human lymphocytes. J. Immunol. 157: 4908–4917.PubMedGoogle Scholar
  45. 45.
    Musso T, Deaglio S, Franco L, Calosso L, Badolato R, Garbarino G, Dianzani U and Malavasi F. 2001. CD38 expression and functional activities are upregulated by IFN-y on human monocytes and monocytic cell lines. Leuk. Biol. 69: 605–612.Google Scholar
  46. 46.
    Matsunaga T, Kudo J, Takahashi K, Dohmen K, Hayashida K, Okamura S, Ishibashi H and Niho Y. 1996. Rotenone, a mitochondrial NADH dehydrogenase inhibitor, induces cell surface expression of CD 13 and CD38 and apoptosis in HL-60 cells. Leuk. Lympho. 20: 487–494.CrossRefGoogle Scholar
  47. 47.
    Chini EN, de Toledo FG, Thompson MA and Dousa TP. 1997. Effect of estrogen upon cyclic ADP ribose metabolism: p-estradiol stimulates ADP ribosyl cyclase in rat uterus. Proc. Natl. Acad. Sci. USA 94: 5872–5876.PubMedCrossRefGoogle Scholar
  48. 48.
    Abraham E, Carmody A, Shenkar R, Arcaroli J. 2000. Neutrophils as early immunologic factors in hemorrhage-induced acute lung injury. Am. J. Physiol. 279: 1137–1145.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Kapil Mehta
    • 1
  1. 1.Department of BioimmunotherapyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations